CargoAdmin, Bureaucrats, Moderators (CommentStreams), fileuploaders, Interface administrators, newuser, Push subscription managers, Suppressors, Administrators
14,662
edits
Sanofi: Difference between revisions
m
Text replacement - "Reuters" to "Reuters"
m (Text replacement - "The Wall Street Journal" to "The Wall Street Journal") |
m (Text replacement - "Reuters" to "Reuters") |
||
| Line 86: | Line 86: | ||
===Name change, acquisitions and investments=== | ===Name change, acquisitions and investments=== | ||
The company dropped the -Aventis suffix of its name on May 6, 2011, after receiving approval at its [[annual general meeting]]. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.<ref>{{cite news |last=Mennella |first=Noelle |date=6 May 2011 |title=Sanofi changes name, pace of acquisitions to slow |work= | The company dropped the -Aventis suffix of its name on May 6, 2011, after receiving approval at its [[annual general meeting]]. The reason given by the company for the change was to make its name easier to pronounce in countries such as China.<ref>{{cite news |last=Mennella |first=Noelle |date=6 May 2011 |title=Sanofi changes name, pace of acquisitions to slow |work=Reuters |url=https://www.reuters.com/article/sanofi-idUSLDE74521Z20110506 |access-date=7 May 2011}}</ref> | ||
In 2011, [[Genzyme Corporation]] was acquired for around $20.1 billion. This biotechnology company, headquartered in Cambridge, Massachusetts, specializes in the treatment of [[orphan diseases]], renal diseases, endocrinology, oncology, and biosurgery.<ref>{{cite news |last=Nicholson |first=Chris V. |date=16 February 2011 |title=Sanofi Agrees to Buy Genzyme for $20.1 Billion |work=The New York Times |url=https://dealbook.nytimes.com/2011/02/16/sanofi-agrees-to-buy-genzyme-for-at-least-20-1-billion/ |access-date=27 November 2019}}</ref> | In 2011, [[Genzyme Corporation]] was acquired for around $20.1 billion. This biotechnology company, headquartered in Cambridge, Massachusetts, specializes in the treatment of [[orphan diseases]], renal diseases, endocrinology, oncology, and biosurgery.<ref>{{cite news |last=Nicholson |first=Chris V. |date=16 February 2011 |title=Sanofi Agrees to Buy Genzyme for $20.1 Billion |work=The New York Times |url=https://dealbook.nytimes.com/2011/02/16/sanofi-agrees-to-buy-genzyme-for-at-least-20-1-billion/ |access-date=27 November 2019}}</ref> | ||
| Line 110: | Line 110: | ||
In May 2020, [[Regeneron]] announced that it would repurchase around $5 billion of its shares held directly by Sanofi. Before the transaction, Sanofi had held 23.2 million Regeneron shares.<ref>{{cite news |date=25 May 2020 |title=U.S.' Regeneron to buy back $5 billion stake held by Sanofi |work=Reuters|url=https://uk.reuters.com/article/us-sanofi-regeneron-idUKKBN2311TC |archive-url=https://web.archive.org/web/20200527014812/https://uk.reuters.com/article/us-sanofi-regeneron-idUKKBN2311TC |url-status=dead |archive-date=27 May 2020 |access-date=11 December 2020}}</ref> In June, the company announced that it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments.<ref>{{cite news |last=Mishra |first=Sudip Kar-Gupta, Manas |date=23 June 2020 |title=Sanofi clinches $2 billion vaccines deal with Translate Bio |work=Reuters|url=https://uk.reuters.com/article/uk-sanofi-translate-bio-idUKKBN23U0LF |archive-url=https://web.archive.org/web/20200624190925/https://uk.reuters.com/article/uk-sanofi-translate-bio-idUKKBN23U0LF |url-status=dead |archive-date=24 June 2020 |access-date=11 December 2020 |via=uk.reuters.com}}</ref> The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It used recombinant protein-based technology for Sanofi's flu vaccine along with [[GlaxoSmithKline|GSK]]'s pandemic technology and was seeking regulatory approval by the first half of 2021.<ref>{{cite news |date=29 July 2020 |title=Coronavirus vaccine: UK signs deal with GSK and Sanofi |publisher=BBC News |url=https://www.bbc.com/news/business-53577637 |access-date=11 December 2020 }}</ref> Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses.<ref>{{Cite web |title=U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine |date=31 July 2020 |url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html |publisher=CNBC}}</ref> In August, Sanofi announced that it would acquire Principia Biopharma for $3.7 billion, acquiring its [[BTK inhibitor]] program.<ref>{{Cite web |title=Sanofi Acquires Principia Biopharma in $3.6 Billion Deal |url=https://www.biospace.com/article/sanofi-snaps-up-principa-biopharma-and-its-btk-program-for-100-per-share/ |access-date=11 December 2020 |website=BioSpace|date=17 August 2020 }}</ref><ref>{{Cite web |title=Sanofi to acquire Principia Biopharma |url=https://www.biospace.com/article/sanofi-to-acquire-principia-biopharma/ |access-date=11 December 2020 |website=BioSpace}}</ref><ref>{{cite news |last=Kar-Gupta |first=Sudip |date=17 August 2020 |title=Sanofi in hunt for specialty drugs with $3.7 billion deal for U.S.-based Principia |work=Reuters|url=https://uk.reuters.com/article/us-principia-m-a-sanofi-idUKKCN25D0DV |archive-url=https://web.archive.org/web/20200817141118/https://uk.reuters.com/article/us-principia-m-a-sanofi-idUKKCN25D0DV |url-status=dead |archive-date=17 August 2020 |access-date=11 December 2020 |via=uk.reuters.com}}</ref> The acquisition was completed in September 2020.<ref>{{Cite web |date=2020-09-29 |title=Sanofi concludes acquisition of Principia Biopharma |url=https://www.expresspharma.in/latest-updates/sanofi-concludes-acquisition-of-principia-biopharma/ |access-date=2020-09-29 |website=Express Pharma |language=en-US}}</ref> In November, Sanofi announced that it would acquire Kiadis Pharma for €308 million (around $359 million, or €5.45 per share), expanding its immuno-oncology pipeline with the acquisition of Kiadis's three clinical compounds: K-NK002 in Phase II trials for [[hematopoietic stem cell]] transplants in blood cancer, K-NK003 for relapsed or refractory [[acute myeloid leukemia]], and K-NK-ID101 for [[COVID-19]].<ref>{{Cite web |title=Sanofi Picks Up Kiadis and Its Immuno-Oncology Assets for $359 Million |url=https://www.biospace.com/article/sanofi-offers-to-acquire-kiadis-for-359-million/ |access-date=11 December 2020 |website=BioSpace|date=2 November 2020 }}</ref> | In May 2020, [[Regeneron]] announced that it would repurchase around $5 billion of its shares held directly by Sanofi. Before the transaction, Sanofi had held 23.2 million Regeneron shares.<ref>{{cite news |date=25 May 2020 |title=U.S.' Regeneron to buy back $5 billion stake held by Sanofi |work=Reuters|url=https://uk.reuters.com/article/us-sanofi-regeneron-idUKKBN2311TC |archive-url=https://web.archive.org/web/20200527014812/https://uk.reuters.com/article/us-sanofi-regeneron-idUKKBN2311TC |url-status=dead |archive-date=27 May 2020 |access-date=11 December 2020}}</ref> In June, the company announced that it had agreed a potential $2 billion deal with Translate Bio, expanding an already existing collaboration for COVID-19 treatments.<ref>{{cite news |last=Mishra |first=Sudip Kar-Gupta, Manas |date=23 June 2020 |title=Sanofi clinches $2 billion vaccines deal with Translate Bio |work=Reuters|url=https://uk.reuters.com/article/uk-sanofi-translate-bio-idUKKBN23U0LF |archive-url=https://web.archive.org/web/20200624190925/https://uk.reuters.com/article/uk-sanofi-translate-bio-idUKKBN23U0LF |url-status=dead |archive-date=24 June 2020 |access-date=11 December 2020 |via=uk.reuters.com}}</ref> The company agreed to produce 60 million doses of a coronavirus vaccine for the United Kingdom government in July 2020. It used recombinant protein-based technology for Sanofi's flu vaccine along with [[GlaxoSmithKline|GSK]]'s pandemic technology and was seeking regulatory approval by the first half of 2021.<ref>{{cite news |date=29 July 2020 |title=Coronavirus vaccine: UK signs deal with GSK and Sanofi |publisher=BBC News |url=https://www.bbc.com/news/business-53577637 |access-date=11 December 2020 }}</ref> Sanofi also agreed to a $2.1 billion deal with the United States for 100 million doses.<ref>{{Cite web |title=U.S. agrees to pay Sanofi and GSK $2.1 billion for 100 million doses of coronavirus vaccine |date=31 July 2020 |url=https://www.cnbc.com/2020/07/31/us-agrees-to-pay-sanofi-and-gsk-2point1-billion-for-100-million-doses-of-coronavirus-vaccine.html |publisher=CNBC}}</ref> In August, Sanofi announced that it would acquire Principia Biopharma for $3.7 billion, acquiring its [[BTK inhibitor]] program.<ref>{{Cite web |title=Sanofi Acquires Principia Biopharma in $3.6 Billion Deal |url=https://www.biospace.com/article/sanofi-snaps-up-principa-biopharma-and-its-btk-program-for-100-per-share/ |access-date=11 December 2020 |website=BioSpace|date=17 August 2020 }}</ref><ref>{{Cite web |title=Sanofi to acquire Principia Biopharma |url=https://www.biospace.com/article/sanofi-to-acquire-principia-biopharma/ |access-date=11 December 2020 |website=BioSpace}}</ref><ref>{{cite news |last=Kar-Gupta |first=Sudip |date=17 August 2020 |title=Sanofi in hunt for specialty drugs with $3.7 billion deal for U.S.-based Principia |work=Reuters|url=https://uk.reuters.com/article/us-principia-m-a-sanofi-idUKKCN25D0DV |archive-url=https://web.archive.org/web/20200817141118/https://uk.reuters.com/article/us-principia-m-a-sanofi-idUKKCN25D0DV |url-status=dead |archive-date=17 August 2020 |access-date=11 December 2020 |via=uk.reuters.com}}</ref> The acquisition was completed in September 2020.<ref>{{Cite web |date=2020-09-29 |title=Sanofi concludes acquisition of Principia Biopharma |url=https://www.expresspharma.in/latest-updates/sanofi-concludes-acquisition-of-principia-biopharma/ |access-date=2020-09-29 |website=Express Pharma |language=en-US}}</ref> In November, Sanofi announced that it would acquire Kiadis Pharma for €308 million (around $359 million, or €5.45 per share), expanding its immuno-oncology pipeline with the acquisition of Kiadis's three clinical compounds: K-NK002 in Phase II trials for [[hematopoietic stem cell]] transplants in blood cancer, K-NK003 for relapsed or refractory [[acute myeloid leukemia]], and K-NK-ID101 for [[COVID-19]].<ref>{{Cite web |title=Sanofi Picks Up Kiadis and Its Immuno-Oncology Assets for $359 Million |url=https://www.biospace.com/article/sanofi-offers-to-acquire-kiadis-for-359-million/ |access-date=11 December 2020 |website=BioSpace|date=2 November 2020 }}</ref> | ||
In January 2021, Sanofi announced that it would buy the British biotech Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion.<ref>{{cite news|last=White|first=Sarah|date=2021-01-11|title=Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy|language=en|work=Reuters|url=https://www.reuters.com/article/us-sanofi-immunotherapy-idUSKBN29G0RT|access-date=2021-01-11}}</ref><ref>{{Cite press release|url=https://www.globenewswire.com/news-release/2021/01/11/2155914/0/en/Sanofi-to-acquire-Kymab-adding-KY1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-OX40L.html|title = Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L|date = 11 January 2021}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/sanofi-boosts-immunology-pipeline-with-1-4-billion-acquisition-of-kymab/?s=79|title = Sanofi Ups Immunology Game with $1.4 Billion Acquisition of Kymab| date=11 January 2021 }}</ref> In April, the business announced that it would acquire Tidal Therapeutics for up to $470m.<ref>{{Cite web|url=https://www.biospace.com/article/sanofi-snatches-up-tidal-therapeutics-in-470-deal/?s=79|title = Sanofi Snatches up Tidal Therapeutics in $470 Million Deal| date=9 April 2021 }}</ref> in August the company announced that it would acquire Translate Bio and its mRNA vaccine technology for $3.2 billion.<ref>{{cite news|url=https://www.reuters.com/article/us-health-coronavirus-sanofi-translate-b/sanofi-bets-on-mrna-vaccines-beyond-covid-in-3-2-billion-translate-bio-deal-idUSKBN2F328C|title=EXCLUSIVE Sanofi offers to buy U.S. Biotech, mRNA partner Translate Bio -sources|work=Reuters|date=3 August 2021|last1=Blamont|first1=Matthias}}</ref> On 8 September 2021, Sanofi announced that it would acquire US biotech company [[Kadmon Corporation]] for $1.9 billion<ref>{{cite news|url=https://www.reuters.com/business/healthcare-pharmaceuticals/frances-sanofi-buy-us-biopharma-firm-kadmon-19-bln-deal-2021-09-08/ |title=France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal|work=Reuters|date=2021-09-08|access-date=2021-09-08}}</ref> On 18 November 2021, it was reported that Sanofi would be investing $180 million in French startup [[Owkin]], whose predictive algorithms aim to improve the research and development of new cures against cancer.<ref>{{Cite web|last=Rosemain|first=Mathieu|title=Drugmaker Sanofi invests $180 million in French AI startup Owkin - Metro US|url=https://www.metro.us/drugmaker-sanofi-invests-180/|access-date=2021-11-18|website=metro.us|date=18 November 2021 |language=en-US}}</ref> In December, the company announced that it would acquire Origimm Biotechnology GmbH and its acne vaccine candidate (ORI-001),<ref>{{Cite web|url=https://www.biospace.com/article/sanofi-to-acquire-origimm-biotechnology-in-first-move-to-treat-acne-with-vaccine-based-immunotherapy-/|title=Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy|website=BioSpace}}</ref><ref>{{Cite news|url=https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-group-sanofi-buy-origimm-biotechnology-boost-vaccines-business-2021-12-01/|title=Sanofi to buy Origimm Biotechnology for acne vaccine candidate|date=1 December 2021|work=Reuters}}</ref> as well as Amunix Pharmaceuticals, for an initial $1 billion plus potentially $200 million in additional milestones.<ref>{{cite news| url = https://www.reuters.com/markets/deals/sanofi-1-bln-deal-buy-us-based-amunix-pharma-2021-12-21/| title = Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma| website = | In January 2021, Sanofi announced that it would buy the British biotech Kymab Ltd and its potential first-in-class drug candidate – KY1005 –- for $1.45 billion.<ref>{{cite news|last=White|first=Sarah|date=2021-01-11|title=Sanofi buys Kymab for up to $1.5 billion to expand in immunotherapy|language=en|work=Reuters|url=https://www.reuters.com/article/us-sanofi-immunotherapy-idUSKBN29G0RT|access-date=2021-01-11}}</ref><ref>{{Cite press release|url=https://www.globenewswire.com/news-release/2021/01/11/2155914/0/en/Sanofi-to-acquire-Kymab-adding-KY1005-to-its-pipeline-a-human-monoclonal-antibody-targeting-key-immune-system-regulator-OX40L.html|title = Sanofi to acquire Kymab, adding KY1005 to its pipeline, a human monoclonal antibody targeting key immune system regulator OX40L|date = 11 January 2021}}</ref><ref>{{Cite web|url=https://www.biospace.com/article/sanofi-boosts-immunology-pipeline-with-1-4-billion-acquisition-of-kymab/?s=79|title = Sanofi Ups Immunology Game with $1.4 Billion Acquisition of Kymab| date=11 January 2021 }}</ref> In April, the business announced that it would acquire Tidal Therapeutics for up to $470m.<ref>{{Cite web|url=https://www.biospace.com/article/sanofi-snatches-up-tidal-therapeutics-in-470-deal/?s=79|title = Sanofi Snatches up Tidal Therapeutics in $470 Million Deal| date=9 April 2021 }}</ref> in August the company announced that it would acquire Translate Bio and its mRNA vaccine technology for $3.2 billion.<ref>{{cite news|url=https://www.reuters.com/article/us-health-coronavirus-sanofi-translate-b/sanofi-bets-on-mrna-vaccines-beyond-covid-in-3-2-billion-translate-bio-deal-idUSKBN2F328C|title=EXCLUSIVE Sanofi offers to buy U.S. Biotech, mRNA partner Translate Bio -sources|work=Reuters|date=3 August 2021|last1=Blamont|first1=Matthias}}</ref> On 8 September 2021, Sanofi announced that it would acquire US biotech company [[Kadmon Corporation]] for $1.9 billion<ref>{{cite news|url=https://www.reuters.com/business/healthcare-pharmaceuticals/frances-sanofi-buy-us-biopharma-firm-kadmon-19-bln-deal-2021-09-08/ |title=France's Sanofi to buy U.S. biopharma firm Kadmon in $1.9 bln deal|work=Reuters|date=2021-09-08|access-date=2021-09-08}}</ref> On 18 November 2021, it was reported that Sanofi would be investing $180 million in French startup [[Owkin]], whose predictive algorithms aim to improve the research and development of new cures against cancer.<ref>{{Cite web|last=Rosemain|first=Mathieu|title=Drugmaker Sanofi invests $180 million in French AI startup Owkin - Metro US|url=https://www.metro.us/drugmaker-sanofi-invests-180/|access-date=2021-11-18|website=metro.us|date=18 November 2021 |language=en-US}}</ref> In December, the company announced that it would acquire Origimm Biotechnology GmbH and its acne vaccine candidate (ORI-001),<ref>{{Cite web|url=https://www.biospace.com/article/sanofi-to-acquire-origimm-biotechnology-in-first-move-to-treat-acne-with-vaccine-based-immunotherapy-/|title=Sanofi to acquire Origimm Biotechnology in first move to treat acne with vaccine-based immunotherapy|website=BioSpace}}</ref><ref>{{Cite news|url=https://www.reuters.com/business/healthcare-pharmaceuticals/healthcare-group-sanofi-buy-origimm-biotechnology-boost-vaccines-business-2021-12-01/|title=Sanofi to buy Origimm Biotechnology for acne vaccine candidate|date=1 December 2021|work=Reuters}}</ref> as well as Amunix Pharmaceuticals, for an initial $1 billion plus potentially $200 million in additional milestones.<ref>{{cite news| url = https://www.reuters.com/markets/deals/sanofi-1-bln-deal-buy-us-based-amunix-pharma-2021-12-21/| title = Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma| website = Reuters| date = 21 December 2021}}</ref> | ||
In April 2022, Sanofi broke ground on its biggest industrial investment, a $638m vaccine and enzymes production facility in [[Tuas]], [[Singapore]], targeted for completion in 2025.<ref>{{cite web| url = https://www.straitstimes.com/singapore/health/pharma-giant-sanofi-breaks-ground-on-638m-vaccine-facility-in-singapore| title = Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma |first=Joyce |last=Teo|work=The Straits Times|date=2022-04-20|access-date=2022-04-30}}</ref> | In April 2022, Sanofi broke ground on its biggest industrial investment, a $638m vaccine and enzymes production facility in [[Tuas]], [[Singapore]], targeted for completion in 2025.<ref>{{cite web| url = https://www.straitstimes.com/singapore/health/pharma-giant-sanofi-breaks-ground-on-638m-vaccine-facility-in-singapore| title = Sanofi in $1 bln deal to buy U.S.-based Amunix Pharma |first=Joyce |last=Teo|work=The Straits Times|date=2022-04-20|access-date=2022-04-30}}</ref> | ||